Table 3 Bivariate and multivariate analysis of factors associated with cognitive impairment among SLE patients

Depression, n (%)^*

13 (54.17)

11 (45.83)

0.83 (0.34–2.05)

0.867

Anxiety, n (%)^*

24 (54.54)

20 (45.45)

0.81 (0.38–1.73)

0.723

Disease duration, months, Median (Q1-Q3) ^****

48 (15–11)

56 (24–109.50)

-

0.467

Age, years, Mean (SD) ^***

35.69 (10.80)

32.67 (9.02)

-

0.115

1.03 (0.98–1.07)

0.271

Disease activity, Median (Q1-Q3) ^****

0 (0–2)

0 (0–4)

-

0.629

Comorbidities, n (%)^*

28 (68.29)

13 (31.71)

1.99 (0.90–4.42)

0.133

0.53 (0.21–1.36)

0.186

Steroid dose, Median (Q1-Q3) ^****

4 (0.60–4)

4 (1.55–6)

-

0.689

Immunosuppressants medications

Hydroxychloroquine, n (%)^*

47 (59.49)

32 (40.51)

1.25 (0.57–2.74)

0.725

Mycophenolate sodium, n (%)^*

27 (56.25)

21 (43.75)

0.90 (0.43–1.90)

0.932

Azathioprine, n (%)^**

11 (57.89)

8 (42.10)

1.01 (0.37–2.72)

1.000

Methotrexate, n (%)^*

4 (66.67)

2 (33.33)

1.49 (0.26–8.49)

1.000

Cyclosporine, n (%)

0 (0)

4 (100)

-

-

Organ Involvement

Musculoskeletal, n (%)^**

62 (58.49)

44 (41.51)

1.41 (0.38–5.16)

0.741

Mucocutaneous, n (%)^**

60 (57.14)

45 (42.86)

0.76 (0.21–2.76)

0.758

Renal, n (%)^*

23 (50)

23 (50)

0.59 (0.28–1.26)

0.238

2.01 (0.85–4.75)

0.113

Hematology, n (%)^*

17 (54.84)

14 (45.16)

0.85 (0.37–1.95)

0.863

Neuropsychiatric, n (%)^*

11 (47.83)

12 (52.17)

0.61 (0.24–1.52)

0.400

Education level, n (%)^*

Primary

10 (76.92)

3 (23.08)

5.00 (1.21–20.71)

0.026

4.48 (1.02–19.72)

0.047^******

Secondary

39 (67.24)

19 (32.76)

3.08 (1.37–6.92)

0.007

3.54 (1.46–8.58)

0.005^******

Tertiary

18 (40)

27 (60)

Refference

Refference